Ipsen (IPN.PA)

Executive Summary

Ipsen is a global biopharmaceutical company headquartered in Paris, specializing in oncology, rare diseases, and neuroscience. With a market valuation of approximately $12.8 billion, the company leverages its expertise in small molecules and biologics to address high unmet medical needs. Its commercial portfolio includes six approved products, such as Somatuline® (lanreotide) for neuroendocrine tumors and acromegaly, and Dysport® (abobotulinumtoxinA) for therapeutic and aesthetic indications. Ipsen's pipeline is focused on advancing novel therapies, notably elafibranor (Iqirvo®) for primary biliary cholangitis (PBC), which received accelerated FDA approval in 2024 and is now being commercialized. The company also partners with organizations like Genfit and Clementia to expand its rare disease portfolio, including palovarotene for fibrodysplasia ossificans progressiva (FOP). Recent clinical data and regulatory progress underscore Ipsen's commitment to innovation, while its strong cash position enables strategic business development to bolster future growth. Ipsen's near-term growth is driven by the launch of elafibranor in PBC and ongoing label expansion efforts. The company is actively pursuing regulatory approvals in additional markets and evaluating the drug's potential in other cholestatic liver diseases, such as primary sclerosing cholangitis (PSC). Additionally, Ipsen's neuroscience franchise continues to generate steady revenue from Dysport, and its oncology pipeline, including a next-generation somatostatin analog, is progressing. Despite competition in key therapeutic areas, Ipsen's focused strategy, robust pipeline, and commercial execution position it for sustained value creation. However, investor sentiment will hinge on real-world uptake of elafibranor and upcoming clinical readouts in rare diseases.

Upcoming Catalysts (preview)

• Q4 2026Elafibranor (Iqirvo) PBC launch milestones and quarterly sales update75% success
• Q4 2026Regulatory decision on palovarotene for FOP in the US (FDA)60% success
• Q2 2027Phase 3 data readout for elafibranor in primary sclerosing cholangitis (PSC)50% success